Metallothionein Lower Under-Expression in Benign Tumors than That in Malignant Tumors: Systematic Review Article and Meta-Analysis

about

Metallothionein Lower Under-Expression in Benign Tumors than That in Malignant Tumors: Systematic Review Article and Meta-Analysis

Item

http://www.wikidata.org/entity/Q38537586

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Metallothionein Lower Under-Ex ...... view Article and Meta-Analysis

@en

type

Item

label

Metallothionein Lower Under-Ex ...... view Article and Meta-Analysis

@en

prefLabel

Metallothionein Lower Under-Ex ...... view Article and Meta-Analysis

@en

P1476

Metallothionein Lower Under-Ex ...... view Article and Meta-Analysis

@en

P2093

Guinian Wang

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Qinglu Wang

http://www.w3.org/2001/XMLSchema#string

Ruijie Sun

http://www.w3.org/2001/XMLSchema#string

Yue Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Comparison of metallothionein (MT) and Ki-67 antigen expression in benign and malignant thyroid tumours.

Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice

Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

P304

696-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26110140

http://www.w3.org/2001/XMLSchema#string

P932

4475588

http://www.w3.org/2001/XMLSchema#string